<DOC>
	<DOCNO>NCT00849394</DOCNO>
	<brief_summary>This clinical research study look incidence proteinuria ( condition urine contain abnormal amount protein ) cause shortened infusion ( give vein 10 15 minute ) bevacizumab ( medication prescribe colon , lung , breast cancer ) . There currently publish study clinical data look safe shorten infusion bevacizumab relationship side effect proteinuria . We hypothesis shortened infusion bevacizumab result increase risk proteinuria compare standard infusion agent .</brief_summary>
	<brief_title>Evaluation Protein Urine Patients Receiving Bevacizumab</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Patients must 18 year old Patients must receive his/her first dose bevacizumab Patients must sign informed consent Patients receive &gt; 10 mg/kg dos bevacizumab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>bevacizumab</keyword>
	<keyword>proteinuria</keyword>
</DOC>